Hsieh Helen, Frenette Adam, Michaud Laurent, Krishnan Usha, Dal-Soglio Dorothée B, Gottrand Frederic, Faure Christophe
*Esophageal Atresia Clinic Sainte-Justine University Health Centre, Université de Montréal, Montreal, Canada†Reference Centre for Congenital and Malformative Esophageal Diseases, CHU Lille, University Lille2, Lille, France‡Sydney Children's Hospital, Sydney, NSW, Australia§Department of Pathology, Sainte-Justine University Health Centre, Université de Montréal, Montreal, Canada.
J Pediatr Gastroenterol Nutr. 2017 Jul;65(1):e1-e4. doi: 10.1097/MPG.0000000000001558.
Patients with esophageal atresia/tracheoesophageal fistula (EA-TEF) can develop Barrett esophagus as a long-term consequence of their condition. Intestinal metaplasia (IM), a risk factor for developing adenocarcinoma of the esophagus, has not been well characterized in the pediatric population.
Retrospective review of patients with EA-TEF followed at 3 academic pediatric centers between the years 1997 and 2014.
Among 542 children and adolescents, 1.3% (7 patients, 5 girls) were diagnosed with IM based on endoscopy and pathology. Six of the patients had EA-TEF type C, whereas the last patient had a "long gap" type A atresia. Patients were diagnosed with gastric metaplasia either before the IM diagnosis in 4 patients or concomitantly in 3. The median (range) age of diagnosis for gastric metaplasia was 7.9 (range 2-17.2) and for IM 10.9 (2-17.2) years. Gastroesophageal reflux (GER) symptoms were nonspecific. Five patients were on proton pump inhibitor therapy for symptomatic GER at the time of diagnosis of IM. 2 of the 7 patients had previously undergone Nissen fundoplication. One patient, who had undergone a Nissen fundoplication, was restarted on proton pump inhibitor once the diagnosis of IM was made. All patients had repeated endoscopy and dysplasia was not observed with a median follow-up of 1.7 (range 1-4.9) years.
IM occurs in patients with EA-TEF, some as young as 2 years. Therefore, early endoscopic surveillance should be considered in this GER-prone population.
食管闭锁/气管食管瘘(EA-TEF)患者可能会因病情发展而出现巴雷特食管。肠化生(IM)是食管腺癌的一个危险因素,在儿科人群中尚未得到充分研究。
对1997年至2014年间在3个学术性儿科中心接受随访的EA-TEF患者进行回顾性研究。
在542名儿童和青少年中,1.3%(7名患者,5名女孩)经内镜检查和病理诊断为IM。其中6名患者为C型EA-TEF,最后1名患者为“A型长节段”闭锁。4名患者在IM诊断之前被诊断为胃化生,3名患者同时被诊断为胃化生。胃化生诊断的中位(范围)年龄为7.9岁(范围2-17.2岁),IM诊断的中位(范围)年龄为10.9岁(2-17.2岁)。胃食管反流(GER)症状不具特异性。7名患者中有5名在IM诊断时因有症状的GER正在接受质子泵抑制剂治疗。7名患者中有2名之前接受过nissen胃底折叠术。1名接受过nissen胃底折叠术的患者在诊断为IM后重新开始使用质子泵抑制剂。所有患者均接受了重复内镜检查,中位随访1.7年(范围1-4.9年)未观察到发育异常。
IM发生于EA-TEF患者,有些患者年仅2岁。因此,对于这个易患GER的人群,应考虑早期内镜监测。